Corporation
Alexion Pharma Canada
- Meetings this Parliament
- 3
- With MPs
- 1
- Since Nov 2021
- 4
- Active registrations
- 1
Most recent reported meeting: Aug 27, 2026.
Lobbying by Alexion Pharma Canada: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (corporation) In effect since Aug 24, 2026
Filed by Karen Heim, Vice President and General Manager, Alexion Pharma Canada
Lobbyists
- Karen Heim · General Manager
- Leigh Funston · Director Corporate Affairs
- Paul de Zara · Associate Director Market Acces
- Phillipe Renaud · Associate Director Market Access
- Rob Woolstencroft · Head Market Access & Patient Experience
Institutions they may lobby: Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Treasury Board Of Canada Secretariat (TBS)
What they're lobbying on (4)Hide details
- Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board.
- Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals including any health technology assessment-related or other policy discussions that might involve Health Canada and its ongoing relationship with Canada's Drug Agency and/or other pan-Canadian health organizations.
- Engagement with federal officials regarding Innovation, Science and Economic Development Canada’s Biomanufacturing and Life Sciences Strategy and other government policies and programs related to incentivizing research and development activities in Canada.
- Canada’s Innovation and Skills Plan, led by Innovation, Science and Economic Development Canada, specifically aspects related to the pharmaceutical and life sciences sector, including intellectual property protection and attraction of investments in research and development.
Registration 959365-360057-14. Look it up in the official Registry
Reported meetings
Spreadsheet-
Reported by Karen Heim · In-house (corporation)
- Justine Frame · Policy Advisor, Health Canada (HC)
Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals including any health technology assessment-related or other policy discussions that might involve Health Canada and its ongoing relationship with Canada's Drug Agency and/or other pan-Canadian health organizations. Read more
Engagement with federal officials regarding Innovation, Science and Economic Development Canada’s Biomanufacturing and Life Sciences Strategy and other government policies and programs related to incentivizing research and development activities in Canada.
-
Reported by Karen Heim · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Canada’s Innovation and Skills Plan, led by Innovation, Science and Economic Development Canada, specifically aspects related to the pharmaceutical and life sciences sector, including intellectual property protection and attraction of investments in research and development. Read more
Engagement with federal officials regarding Innovation, Science and Economic Development Canada’s Biomanufacturing and Life Sciences Strategy and other government policies and programs related to incentivizing research and development activities in Canada.
-
Reported by Karen Heim · In-house (corporation)
- Raquel Dancho · Member of Parliament
Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals including any health technology assessment-related or other policy discussions that might involve Health Canada and its ongoing relationship with Canada's Drug Agency and/or other pan-Canadian health organizations. Read more
-
Reported by Karen Heim · In-house (corporation)
- Patrick Halley · Asst Deputy Minister, Finance Canada (FIN)
- Gabriel Williams · Policy Analyst, Finance Canada (FIN)
Canada’s Innovation and Skills Plan, led by Innovation, Science and Economic Development Canada, specifically aspects related to the pharmaceutical and life sciences sector, including intellectual property protection and attraction of investments in research and development. Read more
Engagement with federal officials regarding Innovation, Science and Economic Development Canada’s Biomanufacturing and Life Sciences Strategy and other government policies and programs related to incentivizing research and development activities in Canada.
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.